The Application for the Marketing of Trivalent Influenza Virus Subunit Vaccine has been Accepted!
Product Center
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-10-08
- Views:
(Summary description)Recently, Ab&B Bio-Tech Co., Ltd (Ab&B Bio) has received acceptance from the Center for Drug Evaluation (CDE) of the China National Medical Products Administration for its application to market the "trivalent influenza virus subunit vaccine for children aged 6-35 months" and the "trivalent influenza virus subunit vaccine for individuals aged 3 years and above". This acceptance marks the final sprint stage of the first domestic full-dose trivalent influenza virus subunit vaccine for people aged 6 months and above, which is about to be launched!
The Application for the Marketing of Trivalent Influenza Virus Subunit Vaccine has been Accepted!
(Summary description)Recently, Ab&B Bio-Tech Co., Ltd (Ab&B Bio) has received acceptance from the Center for Drug Evaluation (CDE) of the China National Medical Products Administration for its application to market the "trivalent influenza virus subunit vaccine for children aged 6-35 months" and the "trivalent influenza virus subunit vaccine for individuals aged 3 years and above". This acceptance marks the final sprint stage of the first domestic full-dose trivalent influenza virus subunit vaccine for people aged 6 months and above, which is about to be launched!
- Categories:Company news
- Author:
- Origin:
- Time of issue:2024-10-08 11:33
- Views:
Recently, Ab&B Bio-Tech Co., Ltd (Ab&B Bio) has received acceptance from the Center for Drug Evaluation (CDE) of the China National Medical Products Administration for its application to market the "trivalent influenza virus subunit vaccine for children aged 6-35 months" and the "trivalent influenza virus subunit vaccine for individuals aged 3 years and above". This acceptance marks the final sprint stage of the first domestic full-dose trivalent influenza virus subunit vaccine for people aged 6 months and above, which is about to be launched!
Source: Government Service Website of the Center for Drug Evaluation of the National Medical Products Administration
At present, influenza virus remains one of the most important respiratory pathogens threatening human public health. Seasonal influenza outbreaks or occasional cross-species transmission and pandemics of influenza virus have significant impacts on human health and socio-economic development. The WHO Influenza Vaccination Position Paper and the Chinese Center for Disease Control and Prevention's "Technical Guidelines for Influenza Vaccination in China" clearly state that annual influenza vaccination is the most economical and effective measure to prevent influenza, which can significantly reduce the risk of vaccine recipients contracting influenza and developing serious complications.
This year, WHO proposed that the global influenza surveillance network had not detected the B/Yamagata lineage virus since March 2020, and therefore recommended that influenza vaccines should no longer include B/Yamagata lineage components. Ab&B Bio actively responded and acted quickly to complete the market application for the full-dose trivalent influenza virus subunit vaccine for people aged 6 months and above, scientifically responding to influenza prevention and control, and providing a variety of influenza vaccine options for society. In addition, this vaccine is the first trivalent influenza virus subunit vaccine in China to achieve a unified dosage form for people aged 6 months and above, improving the convenience of influenza vaccine administration.
Ab&B Bio always insists on not making simple copies and deeply cultivates the field of subunit influenza technology. As of now, the Ab&B Bio subunit influenza vaccine family has covered: quadrivalent influenza virus subunit vaccines for people aged 6-35 months, quadrivalent influenza virus subunit vaccines for people aged 3 years and above, quadrivalent influenza virus subunit vaccines (adjuvanted) for elderly people, trivalent influenza virus subunit vaccines for people aged 6 months and above, trivalent influenza virus subunit vaccines (adjuvanted) for elderly people, and universal subunit influenza vaccines under development. The company adheres to the mission of caring for life and safeguarding health, and covers the needs of various populations with safe, effective, rich, and precise influenza vaccine series products to assist in influenza prevention and control.
Relevant information
- Exclusive Release | The influenza subunit vaccine "HRK-X® 3" makes its nationwide debut, ushering in a new chapter of scientific protection for all populations! Caring for life, safeguarding health. Ab&B Bio will continue to pursue its mission through concrete actions—ensuring that China has access to globally innovative vaccines and that the world can benefit from China's high-quality vaccines!
- Deepening Strategic Synergy to Jointly Strengthen Public Health Defense: Chongqing Center for Disease Control and Prevention (Chongqing Institute of Preventive Medicine) visited Ab&B Bio for a visit and exchange session. 08-06
- The world's first! The monkeypox mRNA vaccine has obtained dual clinical trial approvals from both China and the United States. 07-02
- Phase I/II Clinical Trial of the Re engineered Respiratory Syncytial Virus Vaccine (CHO Cells)(Adjuvant)Officially Launched 05-13
- The mRNA technology platform has achieved another milestone, with global innovation efforts accelerating. 05-08
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:[email protected] Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us